Aliya Rashid, DO, MPH, on Addressing Gender Inequality in Pivotal CAR T-Cell Trial Paper Authorship

Commentary
Video

The internal medicine resident physician at University of Kansas Medical Center encouraged centers to actively address female minority paper authorship.

“I think that, overall, it needs to be a cultural shift. I think that just raising awareness about this is a great way to trigger some sort of conversation or even just the thought that, hey, why aren't there as many females in hematology? I think that's the most important thing, shifting how we perceive women in this field.”

Over 70% of authors were male and less than 30% were female out of the 13 pivotal trials that led to the approval of chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia (ALL), lymphoma, and myeloma that were published between 2017-2022. These findings were investigated by a group at the University of Kansas Medical Center and were presented in a poster at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California.

The researchers also found that in the last couple of years there has been a trend of improved gender equality in authorship, but the findings may still reflect lower female representation in transplant and cellular therapy fields. CGTLive spoke with study coauthor Aliya Rashid, DO, MPH, internal medicine resident physician, University of Kansas Medical Center, to get her thoughts on possible strategies to bring this issue to attention and begin to equalize the field of opportunity between male and female doctors and researchers.

Click here to read more coverage of ASH 2023.

REFERENCE
Khaliq A, Wesson W, Logan E, et al. The glass wall: Gendered authorship disparities in in CD 19 and BCMA CAR-T clinical trials for lymphoma and myeloma. Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract #2344
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.